IPFL Expands Prototyping & Production Printing Possibilities with New Multi-Material Polyjet Printer

IPFL, experts in plastic machining, fabrication and 3D printing, has begun running the latest J850 Polyjet 3D printer from Stratasys. The machine will support the company’s compilation of 3D printing technologies and expand on its current polyjet capabilities with the J850’s latest advancements.

The Stratasys J850 is the fastest printer within the J- series by the American-Israeli manufacturer, able to produce highly accurate prototypes and tooling from a range of materials. IPFL’s polyjet addition also features a new super high-speed mode, through which the printer can utilize seven materials at once to provide five times more design iterations. This technology has advanced IPFL’s customer service with reliably strong, flexible, and transparent offerings in complex 3D printed parts.

Polyjet’s printing process, involving the distribution of resin droplets that harden under ultraviolet light, is regarded as one of the most accurate additive manufacturing technologies. The J850 offers unprecedented horizontal build layers 14 microns thin on a sizeable build envelope (495x395x195mm). Furthermore, the printer welcomes a variety of new materials, such as VeroVivid rigid photopolymers,

VeroUltraClear glass-like polymers, and ABS-Like: temperature resistant polymer that is tough against shrinkage. Backed by Pantone validation, IPFL now provides these materials in over 600,000 color variations.

IPFL Director Adam Bloomfield, said: “With the Stratasys J850 polyjet, we can further enhance our quality of parts for customer prototyping and production requirements. IPFL offers smooth and accurate parts in a short space of time, and is always committed to servicing its dedicated sectors. Moving forward, the J850 is a significant addition to our production of medical devices and will enhance our suite of 3D printing capabilities.”

For over 50 years IPFL has continually provided quality plastic components for industrial, medical, transport, aero, consumer, defense, and security sectors. The company has utilized polyjet since 2003, producing high precision prototypes with complex geometry and intricate detail. Its materials are medically approved and soluble, leaving pristine parts that can mimic overmolded products. The J850 is set to reduce IPFL’s process downtime from material changeovers with new integrated material bays, and will reduce the need for multiple print processes thanks to the material variety on offer.

SourceIPFL

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”